UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline
UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent
JPMorgan Chase’s third-quarter profit falls 28 percent as revenue slumps and credit costs rise
JPMorgan Chase reported net income of $15,305 million in the third quarter of 2026, down 28 percent from $21,155 million...
Evidence Sheet: Amgen (AMGN)
The standing BullScope yardsticks for Amgen, computed from official filings and refreshed with each new edition.
From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure
The story, briefly The math, meaning what the filed numbers actually show, tells a story of a cannabis retailer that...
Merck’s Split Screen: Margins at a Decade High, a Stock Priced for Catastrophe
Two numbers sit side by side and refuse to make sense together. The 10-K filed in February 2026 shows Merck...
Three FDA Clocks, One Burning Balance Sheet: What BridgeBio’s Latest Filing Actually Shows
Three years ago, BridgeBio Pharma was a research-stage company watching its revenue collapse in a single year, the casualty of...
Evidence Sheet: Abbvie (ABBV)
The standing BullScope yardsticks for Abbvie, computed from official filings and refreshed with each new edition.
ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not
Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a...
Evidence Sheet: Gilead Sciences (GILD)
The standing BullScope yardsticks for Gilead Sciences, computed from official filings and refreshed with each new edition.
Mirum Pharmaceuticals: A Pipeline on Fire, a Price That Went Cold
Three Phase 3 trials hit their primary endpoints in the span of two weeks. The stock is sitting roughly a...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.